Biblio
Allogeneic stem cell transplantation for chronic myeloid leukaemia is safe and effective in high risk patients following second generation tyrosine kinase inhibitors: A single centre's experience. Leuk Res Rep. 2013;2(2):47-50.
. Inhibition of mitochondrial folate metabolism drives differentiation through mTORC1 mediated purine sensing. Nat Commun. 2024;15(1):1931.
In-vivo T-cell depleted reduced-intensity conditioned allogeneic haematopoietic stem-cell transplantation for patients with acute lymphoblastic leukaemia in first remission: results from the prospective, single-arm evaluation of the UKALL14 trial. Lancet Haematol. 2022;9(4):e276-e288.
Leukaemia exposure alters the transcriptional profile and function of BCR::ABL1 negative macrophages in the bone marrow niche. Nat Commun. 2024;15(1):1090.
Novel drug therapies in myeloid leukemia: a patent review. Pharm Pat Anal. 2015;4(3):187-205.
. Targeting BCR-ABL1-positive leukaemias: a review article. Camb Prism Precis Med. 2023;1:e21.
. ULK1 inhibition promotes oxidative stress-induced differentiation and sensitizes leukemic stem cells to targeted therapy. Sci Transl Med. 2021;13(613):eabd5016.